Connect with us

Science & Health

Feds Release Details About Contract To Roll Thousands Of Marijuana Joints



There are just a few weeks left to send in an application to become a federally contracted preparer and distributor of research-grade marijuana.

And if a prospective applicant is still on the fence, the National Institute on Drug Abuse (NIDA) rolled out a 138-page solicitation notice last week that details all of the tasks the contractor will have to complete, including rolling thousands of “standardized marijuana cigarettes.”

The contract is meant to support NIDA’s research into the risks and benefits of various controlled substances and will last for five years starting in September, with the successful awardee receiving anywhere from $50,000 to nearly $20 million to get the job done.

There have been plenty of jokes about the opening, with some people volunteering for the job after media reports about it went viral. But in all seriousness, the criterion to receive the contract is strict. Individuals must be authorized to handle Schedule I drugs, pass a background check and have a facility that can adequately store and secure the research drug products. They must also be equipped to conduct thorough analyses on the substances’ purity, stability and dosage forms.

The selected contractor is barred from using “contract funds to support activities that promote the legalization of any drug or other substance included in schedule I of… the Controlled Substances Act, except for normal and recognized executive-congressional communications,” according to the notice.

That requirement isn’t necessarily imposed because the role involves working with controlled substances, though. Among other other general congressionally mandated riders attached to research contracts are bans on using funds “to maintain or establish a computer network unless such network blocks the viewing, downloading, and exchanging of pornography” or “to advocate or promote gun control.”

In any case, rolling thousands of joints is in fact a big part of the job. But just so you know, the contractor is explicitly prohibited from consuming any “material developed, modified, or delivered by or to the Government under this contract, or any subsequent modification of such material.”

NIDA outlines all of the various tasks required under the contract in a lengthy documents, but here are some of the highlights:

  • Manufacture, analyze, store, and ship marijuana cigarettes as required by NIDA
  • Acquire hard-to-find controlled and uncontrolled bulk drugs, and other chemical compounds of interest from DEA, commercial sources (including import from international sources), or any other source as required by NIDA.
  • Analyze cannabis materials and their preparations, such as Δ8 -tetrahydrocannabinol (delta-8-THC), Δ9 -tetrahydrocannabinol (delta-9-THC), cannabidiol, cannabichromene, cannabinol, and Δ9 -THC acids and determine their relative ratios in such preparations.
  • Develop and produce standardized reconstituted cannabis preparations, such as delta-9- tetrahydrocannabinol (Δ9 -THC), cannabis extract, cannabinoid parenteral, or any other dosage forms.
  • Prepare reference standards for qualitative and quantitative identification of cannabinoids and other drugs of abuse, prepare quantitative reference standards of cannabinoids and other drugs in serum or urine, and assess the stability of these preparations
  • Serve as NIDA’s drug repository, store controlled and uncontrolled drugs and other research chemical compounds, drug dosage forms, and marijuana and nicotine research cigarettes in proper storage conditions, such as in a secure, DEA approved vault, and in appropriate freezers as necessary
  • Determine the purity and stability of bulk drugs and other chemical compounds in the NIDA drug supply inventory periodically, or as required by the NIDA Contracting Officer’s Representative
  • Maintain active inventory of all required bulk drugs and other chemical compounds for research purposes
  • Store and ship bulk drugs and other chemical compounds for research as required by NIDA

Why is NIDA undertaking this contract? According to the agency, there has been a spike in demand for research-grade drug materials due to a “combination of factors, such as increased regulatory requirements that tend to discourage commercial availability and rapidly expanding research efforts in the area of drug abuse.”

“Therefore, the National Institute on Drug Abuse acquires, prepares/manufactures, analyzes, stores, bulk chemicals, drug dosage forms, including marijuana and nicotine research cigarettes, and makes them available to researchers for drug abuse and related research,” NIDA wrote.

The demand for marijuana is especially high. A sample of the task at hand calls for the manufacturing of joints of varying potency:

  • For proposal purposes, manufacture the following:
    25,000 Standardized marijuana cigarettes, Placebo (THC content, 0.0%)
    25,000 Standardized marijuana cigarettes, Low (THC content, 1.0-2.5%)
    25,000 Standardized marijuana cigarettes, Medium (THC content, 2.5 – 3.5%)
    50,000 Standardized marijuana cigarettes, High (THC content, 3.5 – 5.0%)
  • For proposal purposes, manufacture the following:
    25,000 Standardized marijuana cigarettes, Placebo (CBD content, 0.0%)
    25,000 Standardized marijuana cigarettes, Low (CBD content, 1.0-2.5%)
    25,000 Standardized marijuana cigarettes, Medium (CBD content, 2.5 – 3.5%)
    50,000 Standardized marijuana cigarettes, High (CBD content, 3.5 – 7.0%)
  • For proposal purposes, manufacture the following (by hand rolling):
    Produce 1,000 standardized marijuana cigarettes containing a high concentration of delta-9- THC, or cannabidiol (CBD) or both (greater than 5.0%) or as required by the NIDA COR.

It’s not exactly clear what’s behind the hand-rolling specification in the last bullet point above.

The deadline to submit applications is May 24, and contractors’ personnel must be prepared to pass background checks.

The EPA Is Funding Research On Using Hemp As A Sustainable Alternative To Concrete

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Kyle Jaeger is Marijuana Moment's Los Angeles-based associate editor. His work has also appeared in High Times, VICE and attn.

Science & Health

CBD Might Help You Cut Back On Drinking Alcohol And Reduce Its Damaging Effects, Study Says



CBD, the widely available cannabinoid touted for various health benefits, may have the potential to help people with serious alcohol issues, according to a new review of current scientific evidence.

Not only does cannabidiol appear to “facilitate drinking reduction,” the paper’s authors write, but research also shows the compound “may provide idiosyncratic protection to the liver and brain, which could reduce the development and impact of alcohol-related liver disease and alcohol-related brain injury.”

The review, which is awaiting publication in the journal Frontiers in Pharmacology, offers a comprehensive look at how promising the data is so far regarding the effectiveness of CBD on alcohol use disorders (AUD). The authors, however, also call for human clinical trials, of which none have been published to date, to “pave the way for testing new harm reduction approaches in AUD.”

Researchers in France and Belgium reviewed 26 previous studies published between 1974 and June 2018 that explored the effects of CBD on animal subjects dosed with ethanol. They found several studies that showed CBD can reduce alcohol consumption. In one, for example, researchers discovered that mice administered CBD were less motivated to work (in this case, push a lever) for access to a liquid solution that included 8 percent of ethanol.

“Experimental studies converge to find that CBD reduces the overall level of alcohol drinking in animal models of AUD by reducing ethanol intake, motivation for ethanol, relapse, and by decreasing anxiety and impulsivity.”

Other studies found that mice regularly dosed with the non-intoxicating marijuana compound were also less likely to relapse after they’d been weaned off alcohol, even when they were stressed.

Because of its impact on various aspects of the disease (including “intake, motivation, relapse, anxiety and impulsivity”), CBD “could have a significant action on drinking levels in human subjects with AUD” the review’s authors write. They add, however, that it would be useful to have data using binge-drinking models and models that focus on long-term exposure to alcohol.

Via Frontiers in Pharmacology.

The review also highlighted evidence showing CBD could affect alcohol-related liver inflammation. In one study, researchers found that the livers of mice that’d been given the compound prior to being force-fed alcohol every 12 hours for five days were less damaged than those of mice not exposed to CBD.

“CBD seems to have valuable therapeutic properties for ethanol-induced liver damage, through multiple mechanisms,” including the reduction of oxidative stress, inflammation control, and the death of certain cells responsible for large amounts of scar tissue, the authors write.

Finally, CBD may also offer added protection to specific areas in the brain susceptible to alcohol-related damage. In one study, the brains of rats who’d binged on alcohol and given CBD were found to have lost “significantly” fewer brain cells in the hippocampus and entorhinal cortex. In those rats, CBD acted as a “neuroprotective antioxidant,” the review states. In another experiment, CBD also appeared to restore the neurological and cognitive functions of rats in acute liver failure.

“CBD has been found to reduce alcohol-related brain damage, preventing neuronal loss by its antioxidant and immunomodulatory properties.”

The authors suggest these overall benefits of CBD regarding problematic alcohol use may be due to the “complex” way the cannabinoid interacts with CB2 receptors, which are located throughout the body.

Currently, the review states, the pharmaceuticals available to help people with AUD stop drinking are “insufficiently effective at a population level, and new therapeutic prospects are needed. Moreover, no drug for reducing alcohol-related harms, either on the brain or the liver, has ever been studied.”

Plus, the authors conclude, “CBD could have many more positive effects in subjects with AUD, including antiepileptic, cardioprotective, anxiolytic, or analgesic ones. Human studies are thus crucially needed to explore the many prospects of CBD in AUD and related conditions.”

Meanwhile, there’s still time to submit public comments to the U.S. Food and Drug Administration on how the federal government should regulate CBD products, including supplements and foods. So far, hundreds of people have submitted information. The public comment period ends July 2.

FDA Is Taking Public Comments On CBD. Here’s How To Make Your Voice Heard

Photo by Kimzy Nanney.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Science & Health

Psychedelics May Help If You Have A Drinking Problem, Study Suggests



On the heels of Denver becoming the first city in the country to decriminalize psilocybin mushrooms, new research suggests that using psychedelic substances may help some people with alcohol use disorder (AUD).

“Findings indicate that, in some cases, naturalistic psychedelic use outside of treatment settings is followed by pronounced and enduring reductions in alcohol misuse,” states the study, which suggests that the substances have “the potential for dramatic change.”

The findings, published in the Journal of Psychopharmacology last week, support past studies that link psychedelic use in clinical and religious settings with a decrease in unhealthy alcohol consumption.

Researchers from Johns Hopkins University School of Medicine were interested in getting a better understanding of people’s experiences with using psilocybin, LSD and other mind-altering substances in a non-clinical, natural environment (at home, for example). They utilized an anonymous online survey (which remained accessible from October 2015 to August 2017) to ultimately capture the perspectives of 343 adults.

Aside from demographic information, the survey asked participants to take several standard psychiatric assessments regarding alcohol use. They were also asked to explain what their psychedelic experience was like, including what substances they consumed, how intense of a reaction they felt after consumption and what kind of long-term effects they endured.

Most participants, it turns out, were pretty heavy drinkers prior to their psychedelic experience: About 72 percent reported symptoms that classified them as having severe AUD. They consumed an average of 25.5 drinks per week, and reported having this problem for approximately seven years.

As for their individual mystical experiences, 36 percent reported using psilocybin and 38 percent reported using LSD. Other substances surfaced in the survey responses included ayahuasca and DMT. Most participants said they consumed the drugs for psychological or spiritual exploration.

According to the study, however, the effects lasted well beyond their individual psychedelic journeys.

“Almost all respondents reported that they had greatly reduced or quit drinking alcohol since their reference psychedelic experience as evidenced by a current self-reported mean of 4.3 drinks per week, down from a mean of 25.5 drinks per week before the reference psychedelic experience,” the study’s authors wrote. Only 10 percent stated they had hoped using substance of choice would help them drink less.

At the time they responded to the survey, a majority of participants no longer met the criteria for an AUD. While at least half of the sample experienced some alcohol withdrawal symptoms, including cravings, depression and irritability, many said their symptoms appeared to be “much less severe” compared to previous efforts to reduce their alcohol use. For most of them, the psychedelic experience happened a year or more prior to participating in the study.

“Although such benefits cannot be wholly separated from accompanying reductions in unhealthy alcohol use,” the study’s authors write, “they are consistent with reports of persisting positive effects of psychedelics lasting well beyond the period of acute drug action.”

There are a number of reasons why psychedelic substances may help reduce alcohol misuse, but a key factor that stands out, according to the study, is the spiritual and mystical-like effects the drugs seem to have for some people.

“Spirituality has long been thought to play an important role in recovery from alcohol dependence, and has been posited as a protective factor against alcohol misuse,” the study states. “Spirituality and spiritual practice have also been found to correlate with abstinence in alcohol dependence recovery. Though a major focus of research on spirituality and alcohol misuse has been on Alcoholics Anonymous (AA) and 12-step programs, psychedelics may represent an alternative path to spiritual or otherwise highly meaningful experiences that can help reframe life priorities and values, enhance self-efficacy, and increase motivation to change.”

Continued research into the potential benefits of psychedelics could be profound, especially considering the sheer number of people who struggle with heavy alcohol use. According to the National Institute on Alcohol Abuse and Alcoholism, AUD affects more than 15 million Americans a year.

“When you talk to someone who has managed to overcome addiction, they often talk about how they had to answer big picture questions that connect to what’s important in life,” Matthew Johnson, an associate professor at Johns Hopkins and one of the authors on the study, told Inverse. “Psychedelics prompt those kinds of questions. Even though we have a lot more to explore, I think it’s likely that it’s the intense nature of the drug’s psychological experience that’s underlying its high success rates.”

Lawmakers Schedule Psychedelic Decriminalization Hearing In Oakland

Photo courtesy of Pretty Drugthings.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading


Two Federal Agencies Schedule Meetings To Discuss Marijuana-Related Issues



Two federal agencies recently announced that they will be holding meetings this summer to discuss public health and safety issues related to marijuana.

The Centers for Disease Control and Prevention (CDC) said in a notice published in the Federal Register last week that its Board of Scientific Counselors will convene on July 16 and 17 to tackle a wide variety of topics, including how to prevent the spread of infectious diseases and how to balance intramural and extramural research initiatives.

On the second day of the meeting, which will be open to the public, the panel of experts will also discuss the role of the CDC’s National Center for Injury Prevention and Control in “addressing public health concerns related to marijuana.”

The notice is light on specifics, but the CDC has historically weighed in on the impacts of cannabis use on pregnancy, driving and young people.

Separately, on June 11 and 12, members of the Substance Abuse and Mental Health Services Administration’s Drug Testing Advisory Board will meet for a conversation about federal workplace drug testing policies. Part of that meeting will involve a discussion of “emerging issues surrounding marijuana legalization.”

While the Federal Register filing does not spell out which “emerging issues” will be specifically addressed during the first day’s public session, it also notes that the board will discuss the “impact of cannabis laws on drug testing and future direction” in a closed session on the second day of the meeting.

The federal discussion comes as marijuana reform advocates have stepped up efforts to end the employer practice of penalizing workers who test positive for THC metabolites.

In New York City, for example, a City Council measure prohibiting pre-employment drug testing for cannabis in specific industries and another barring such tests for people on probation were both enacted this month without the mayor’s signature.

While federal marijuana laws continue to strictly prohibit cannabis, the growing legalization movement has forced various agencies to address the issue. Officials from some federal divisions have observed in recent months that the scheduling status of marijuana under federal law has inhibited research into its public health benefits and risks.

In December, representatives from the Food and Drug Administration, Drug Enforcement Administration and National Institute on Drug Abuse were part of a workshop focusing on cannabis research.

U.S. government agencies have also used Federal Register notices to solicit the public’s help in identifying studies about the effects of cannabis on disorders such as Alzheimer’s disease.

NAACP And ACLU Ask Congress To Suspend DEA’s Drug Enforcement Activities

Photo courtesy of Mike Latimer.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Stay Up To The Moment

Marijuana News In Your Inbox

Support Marijuana Moment

Marijuana News In Your Inbox